- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.03. | UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy | ||
| 02.03. | United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition | ||
| 02.03. | BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline | ||
| 02.03. | Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potential | ||
| 02.03. | Roche reports another phase 3 multiple sclerosis win but deaths add to safety questions | ||
| 02.03. | Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock | ||
| 27.02. | Atrium Therapeutics arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates | ||
| 27.02. | Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs | ||
| 27.02. | Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing | ||
| 26.02. | 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process | ||
| 26.02. | Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial | ||
| 26.02. | Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial | ||
| 26.02. | Accent halts solid tumor trial over adverse events, pivots to other lead cancer program | ||
| 25.02. | ARPA-H designates up to $144M for anti-aging medical research | ||
| 25.02. | After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate | ||
| 25.02. | GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug | ||
| 24.02. | Werewolf Therapeutics weighs sale or merger as cash reserves whimper | ||
| 24.02. | Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal | ||
| 24.02. | FDA freezes enrollment in MacroGenics cancer trial after patient death | ||
| 24.02. | Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study | ||
| 24.02. | GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech | ||
| 24.02. | Novo Nordisk's triple G candidate drives 20% weight loss in phase 2 trial in China | ||
| 24.02. | Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months | ||
| 24.02. | Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking | ||
| 23.02. | 'The perfect partner': Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.